ES521370A0 - A PROCEDURE FOR OBTAINING A POLYDOMA. - Google Patents

A PROCEDURE FOR OBTAINING A POLYDOMA.

Info

Publication number
ES521370A0
ES521370A0 ES521370A ES521370A ES521370A0 ES 521370 A0 ES521370 A0 ES 521370A0 ES 521370 A ES521370 A ES 521370A ES 521370 A ES521370 A ES 521370A ES 521370 A0 ES521370 A0 ES 521370A0
Authority
ES
Spain
Prior art keywords
polydoma
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES521370A
Other languages
Spanish (es)
Other versions
ES8504461A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES521370A0 publication Critical patent/ES521370A0/en
Publication of ES8504461A1 publication Critical patent/ES8504461A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES521370A 1982-04-12 1983-04-11 Antibodies having dual specificities, their preparation and uses therefor. Expired ES8504461A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES521370A0 true ES521370A0 (en) 1985-04-16
ES8504461A1 ES8504461A1 (en) 1985-04-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Expired ES8504461A1 (en) 1982-04-12 1983-04-11 Antibodies having dual specificities, their preparation and uses therefor.
ES527963A Granted ES527963A0 (en) 1982-04-12 1983-12-12 AN IMMUNO ASSAY PROCEDURE
ES533931A Expired ES8506091A1 (en) 1982-04-12 1984-07-02 Antibodies having dual specificities, their preparation and uses therefor.
ES533930A Granted ES533930A0 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES537257A Expired ES8606655A1 (en) 1982-04-12 1984-10-31 Antibodies having dual specificities, their preparation and uses therefor.
ES538727A Expired ES8604424A1 (en) 1982-04-12 1984-12-18 Antibodies having dual specificities, their preparation and uses therefor.
ES545247A Expired ES8607386A1 (en) 1982-04-12 1985-07-16 Antibodies having dual specificities, their preparation and uses therefor.

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES527963A Granted ES527963A0 (en) 1982-04-12 1983-12-12 AN IMMUNO ASSAY PROCEDURE
ES533931A Expired ES8506091A1 (en) 1982-04-12 1984-07-02 Antibodies having dual specificities, their preparation and uses therefor.
ES533930A Granted ES533930A0 (en) 1982-04-12 1984-07-02 A PROCEDURE FOR OBTAINING A POLYDOMA
ES537257A Expired ES8606655A1 (en) 1982-04-12 1984-10-31 Antibodies having dual specificities, their preparation and uses therefor.
ES538727A Expired ES8604424A1 (en) 1982-04-12 1984-12-18 Antibodies having dual specificities, their preparation and uses therefor.
ES545247A Expired ES8607386A1 (en) 1982-04-12 1985-07-16 Antibodies having dual specificities, their preparation and uses therefor.

Country Status (11)

Country Link
EP (1) EP0105360A4 (en)
JP (2) JPH0753119B2 (en)
AT (1) AT394577B (en)
AU (1) AU550486B2 (en)
CA (1) CA1213229A (en)
CH (1) CH672796A5 (en)
ES (7) ES8504461A1 (en)
FI (1) FI834529A (en)
GB (4) GB2128631B (en)
IT (1) IT1219778B (en)
WO (1) WO1983003679A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (en) * 1988-09-27 2001-06-18 武田薬品工業株式会社 Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
AU595159B2 (en) * 1984-04-23 1990-03-29 Boston Biomedical Research Institute Incorporated Bispecific antibody determinants
NL8501219A (en) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION.
WO1987006240A1 (en) 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
DE3850542T2 (en) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antibody heteroconjugates for killing HIV-infected cells.
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (en) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol Complex of anti-human cancer protein
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (en) * 1988-12-23 1992-06-30 Biodata Spa IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (en) * 1989-09-21 1994-10-28 Immunotech Partners NOVEL HYDROPHILIC DERIVATIVES, APPLICATION TO DIAGNOSIS AND THERAPEUTICS, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS.
WO1991012023A2 (en) * 1990-02-16 1991-08-22 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (en) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
JP2001515345A (en) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション Compositions and methods for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
DK1545613T3 (en) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
CA2559187C (en) 2004-03-16 2014-02-11 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
ES2715776T3 (en) 2004-11-12 2019-06-06 Seattle Genetics Inc Auristatins that have an aminobenzoic acid unit at the N-terminus
ES2477765T3 (en) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Binding agents to humanized anti-cd70 and their uses
PL1912671T3 (en) 2005-07-18 2018-02-28 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
PL2099823T5 (en) 2006-12-01 2023-02-20 Seagen Inc. Variant target binding agents and uses thereof
ZA200904482B (en) 2007-01-22 2010-09-29 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
AU2009242453B2 (en) 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP3590922A1 (en) 2013-03-15 2020-01-08 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2015053381A1 (en) * 2013-10-10 2015-04-16 幸成 加藤 Anti-podoplanin antibody
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
CN113416229A (en) 2014-09-17 2021-09-21 酵活有限公司 Cytotoxic and antimitotic compounds, and methods of use thereof
JP6412906B2 (en) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Compound, linker-drug and ligand-drug complex
KR20180134351A (en) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. Process for the preparation of pegylated drug-linkers and intermediates thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018175994A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3110096A1 (en) * 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
WO2020229982A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
CA3197167A1 (en) 2020-11-09 2022-05-12 He Xu Antibody drug conjugates
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
ES8606655A1 (en) 1986-04-01
AT394577B (en) 1992-05-11
GB2128631B (en) 1987-02-25
GB2169921A (en) 1986-07-23
CA1213229A (en) 1986-10-28
ES8604424A1 (en) 1986-02-01
ES8503441A1 (en) 1985-02-16
JP2562002B2 (en) 1996-12-11
ATA901883A (en) 1991-10-15
ES533931A0 (en) 1985-06-16
ES545247A0 (en) 1986-05-16
GB8530308D0 (en) 1986-01-22
GB2168998A (en) 1986-07-02
FI834529A0 (en) 1983-12-09
ES8603080A1 (en) 1985-12-01
GB2169921B (en) 1987-03-04
GB2168998B (en) 1987-03-04
IT8320548A0 (en) 1983-04-12
EP0105360A1 (en) 1984-04-18
EP0105360A4 (en) 1986-07-08
ES8504461A1 (en) 1985-04-16
IT1219778B (en) 1990-05-24
FI834529A (en) 1983-12-09
GB8530309D0 (en) 1986-01-22
AU1555983A (en) 1983-11-04
GB8332646D0 (en) 1984-01-11
ES538727A0 (en) 1986-02-01
WO1983003679A1 (en) 1983-10-27
CH672796A5 (en) 1989-12-29
ES527963A0 (en) 1985-02-16
ES8607386A1 (en) 1986-05-16
AU550486B2 (en) 1986-03-20
GB2128631A (en) 1984-05-02
ES8506091A1 (en) 1985-06-16
ES533930A0 (en) 1985-12-01
GB2167086B (en) 1987-03-04
GB2167086A (en) 1986-05-21
ES537257A0 (en) 1986-04-01
JPH0753119B2 (en) 1995-06-07
GB8530310D0 (en) 1986-01-22
JPS6312276A (en) 1988-01-19
JPH0753600A (en) 1995-02-28

Similar Documents

Publication Publication Date Title
ES521370A0 (en) A PROCEDURE FOR OBTAINING A POLYDOMA.
ES519925A0 (en) A PROCEDURE FOR FORMING AN ABSORBENT MATERIAL.
ES534202A0 (en) A PROCEDURE FOR PREPARING NEW CEFEM COMPOUNDS.
ES523195A0 (en) A PROCEDURE FOR PREPARING ALKYL-GLYCOSIDES
ES537668A0 (en) A PROCEDURE FOR PREPARING N-FORMIL-3-PHENOXI-1-AZETIDINCARBOXAMIDES
ES523064A0 (en) PROCEDURE FOR PREPARING AZETIDINS.
ES519652A0 (en) A PROCEDURE FOR OBTAINING S-ADENOSIL-METIONINE.
AR231308A1 (en) A PROCEDURE FOR PREPARING 1-BE-D-RIBOFURANOSIL-1,2,4-TRIAZOLCARBOXAMIDE RIVAVIRINE
ES520364A0 (en) A PROCEDURE FOR PREPARING CEFEM COMPOUNDS.
ES523193A0 (en) A PROCEDURE FOR PREPARING 3-PHENOXI-1-AZETIDINCARBO-XZNMIDAS
FI73942B (en) A UTLOESARE MANOEVRERBAR FOERDELNINGSVENTIL FOER EN UNDER TRYCK STAOENDE BEHAOLLARE.
ES518758A0 (en) A PROCEDURE FOR PREPARING AZETIDINS.
ES538192A0 (en) A PROCEDURE FOR PREPARING A 2-JOKE-6B-9A - DIFLUORO-11B, 17A, 21-TRIHIDROXI-1, 4-PREGNADIEN-3, 20-DIONA-17, 21-DIESTER
ES521813A0 (en) PROCEDURE FOR PREPARING ALCOHYL-POLYSACCHARIDES.
ES520531A0 (en) PROCEDURE FOR PREPARING TIOETERES.
ES524772A0 (en) A PROCEDURE FOR PREPARING PHENYLANILINS-N. SUBSTITUTED.
ES522716A0 (en) A PROCEDURE FOR PREPARING A PIRAZOLE DERIVATIVE.
ES519936A0 (en) A PROCEDURE FOR PREPARING PIRIMIDONE DERIVATIVES.
ES523277A0 (en) A PROCEDURE FOR PREPARING PEPTIDES.
ES527278A0 (en) A PROCEDURE FOR OBTAINING 2,5-ANHYDRO-3,4,6-TRI-O-ACIL-D-ALONSELENOCARBOXAMIDE
ES527108A0 (en) A PROCEDURE FOR PREPARING 2-ALCOXY-5- (PIRIDINIL) PIRIDINAS
NO157221C (en) ELECTROPLETING PROCEDURE.
ES520370A0 (en) A PROCEDURE FOR OBTAINING ISOXAZOLOPYRIMIDINE DERIVATIVES.
ES520879A0 (en) A PROCEDURE FOR PREPARING 1-HYDROXYETHYL-1H-TETRAZOLE-5-THYOL OPTIONALLY PROTECTED.
ES527247A0 (en) A PROCEDURE FOR OBTAINING CEMENT-CONCRETE

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401